S. 775 · 118th Congress · Health

Increasing Transparency in Generic Drug Applications Act

Died in committee570 words Introduced Mar 14, 2023 · Latest action Mar 14, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedMar 14, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 14, 2023

Who lobbies on it

9 organizations · 61 filings · Q1 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Biotechnology Innovation Organization 8 of 8 quarters
    “340B Drug Discount Program ---H.R.8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net Act ---S.1133: 340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight ---PROTECT 340B Act ---SUSTAIN 340B Act Accelerated Approval…”

    Q4 2024 filing · $6.7M lobbying spend in 2024, all issues

  2. Viatris Inc 8 of 8 quarters
    “H.R. 5376 - the Inflation Reduction Act of 2022; from the 117th Congress Part D Formulary Design and Generic Drug Tiering S. 775 - Increasing Transparency in Generic Drug Applications Act HR1503, Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act S. 2129…”

    Q4 2024 filing · $2.5M lobbying spend in 2024, all issues

  3. Association for Accessible Medicines 7 of 8 quarters
    “Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. S.1114 - Expanding Access to Low-Cost Generics Act of 2023. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226…”

    Q4 2024 filing · $2.4M lobbying spend in 2024, all issues

6 more organizations, every filingPROUpgrade

Organizations that named S. 775 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Mar 14, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Mar 14, 2023Introduced in Senate